^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | Kaitanni (cadonilimab) (PD1 inhibitor, CTLA4 inhibitor) + ligufalimab (AK117) (CD47 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The safety and efficacy of cadonilimab in combination with AK117 (anti-CD47 antibody) plus chemotherapy as first-line treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.
Published date:
05/25/2023
Excerpt:
This was an open-label, multi-center phase II study evaluating the safety and efficacy of Cadonilimab +AK117+ XELOX as 1L therapy in advanced HER2(-) G/GEJ adenocarcinoma….Of 8 response-evaluable pts...the ORR by investigator was 75% (6 PRs), tumor shrinkage exceeding 50% was observed in 5 pts (62.5%). The DCR was 100% (8/8)....The study of Cadonilimab combined with AK117 and chemotherapy demonstrated tolerable safety profile and encouraging anti-tumor activities in pts with unresectable locally advanced or metastatic HER2(-) G/GEJ cancer.
Secondary therapy:
CAPOX
DOI:
10.1200/JCO.2023.41.16_suppl.e16050
Trial ID:
